

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method of treating a bone morphogenetic protein (BMP)-related disorder or condition, comprising administering a BMP antagonist to a subject suffering from ~~a BMP-related disorder or condition~~ BMP-induced osteogenesis characterized by heterotopic ossification, wherein the BMP-related disorder or condition is treated, wherein the BMP antagonist is human noggin (hNOG) (SEQ ID NO:2) for local administration, or hNOG Δ B2 (SEQ ID NO:10) for systemic or local administration.
2. (original) The method of claim 1, wherein the BMP-related disorder or condition is heterotopic cranial synostosis, fibrodysplasia ossificans progressiva (FOP), or sclerostosis.
- 3-9. (canceled)
10. (currently amended) A method of blocking biological activity of a bone morphogenetic protein (BMP) in a subject, comprising administering an agent capable of blocking BMP biological activity, wherein the BMP antagonist is human noggin (hNOG) (SEQ ID NO:2) for local administration or hNOG Δ B2 (SEQ ID NO:10) for systemic or local administration.
11. (previously presented) The method of claim 10, wherein the BMP-related disorder or condition is heterotopic cranial synostosis or fibrodysplasia ossificans progressiva (FOP).
- 12-19. (canceled)
20. (currently amended) A method of inhibiting the progress of a bone morphogenetic protein (BMP)-related disorder or condition, comprising administering human noggin

USSN 10/735,345

Office action dated 02 May 2007

Response dated 02 July 2007

Page 3 of 8

(hNOG) (SEQ ID NO:2) for local administration or hNOG Δ B2 (SEQ ID NO:10) for local or systemic administration to a subject suffering from a ~~BMP-related disorder or condition~~ BMP-induced osteogenesis characterized by heterotopic ossification, wherein the BMP-related disorder or condition is treated.